Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01419704|
Recruitment Status : Withdrawn (Study completed at site, no active participants.)
First Posted : August 18, 2011
Last Update Posted : March 3, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Anemia, Sickle Cell Complex and Transfusion-dependent Hemoglobinopathies Thalassemia Diamond-Blackfan Anemia Bone Marrow Failure Syndromes Alpha-Thalassemia Beta-Thalassemia||Biological: Enriched Hematopoetic Stem Cell Infusion||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies|
|Actual Study Start Date :||May 2011|
|Actual Primary Completion Date :||May 2016|
|Actual Study Completion Date :||May 2016|
Experimental: Hemoglobinopathies diagnosed patients
Recipients diagnosed with Hemoglobinopathies are treated with an enriched hematopoetic stem cell infusion from living donor bone marrow
Biological: Enriched Hematopoetic Stem Cell Infusion
Enriched Hematopoetic Stem Cell Infusion
- Proportion of Hemoglobin A and S [ Time Frame: one month to three years ]Red blood cell contents by hemoglobin electrophoresis
- Enriched Hematopoetic Stem Cell Engraftment [ Time Frame: One month to three years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||up to 45 Years (Child, Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
The following criteria are established to identify subjects with hemoglobinopathies, hematologic or bone marrow failure syndromes who have a high predicted morbidity and are at risk for early mortality:
- Patients with alpha or beta thalassemia major.
- Patients with Diamond-Blackfan anemia and other bone marrow failure syndromes, characterized by severe chronic anemia.
- Patients with other complex and transfusion-dependent hemoglobinopathies, including sickle cell disease.
Patients with sickle disease who have one or more of the following:
- Overt or silent stroke
- Neurocognitive impairment
- Pain crises 2 or more episodes per year for past year
- One or more episodes of acute chest syndrome
- Osteonecrosis involving 1 or more joints
- Evidence of retinopathy
- Microalbuminuria or evidence of sickle cell nephropathy
Subjects must also meet all of the following general inclusion criteria:
- Subjects must have a related donor which can consist of Histocompatibility Leukocyte Antigen (HLA)-matched donor up to haploidentical match, mismatched for 1, 2 or 3 HLA-A, B or -DR loci.
- Subjects must have adequate cardiopulmonary function as documented by echocardiogram or radionuclide scan. (Shortening fraction >26% or ejection fraction >40% or ≥ 80% of normal value for age).
- Subjects must have adequate pulmonary function documented by Forced expiratory volume in 1 second (FEV1) of ≥ 50% of predicted for age and/or Diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin) ≥50% of predicted for age for patients > 10 years of age.
- Subjects must have adequate hepatic function as demonstrated by a serum albumin ≥ 3.0 mg/dL, and serum glutamic pyruvic transaminase (SGPT) or serum glutamic oxaloacetic transaminase (SGOT) less than or equal to 5 times the upper limit of normal. Liver biopsy or a liver MRI is necessary if the patient has received chronic transfusions for over a year and/or has a ferritin level of ≥ 1600.
- Subjects must have adequate renal function as demonstrated by a serum creatinine less than or equal to 2 mg/dL. If serum creatinine is ≥ 2 mg/dL, then a creatinine clearance test or nuclear medicine GFR should document GFR of ≥ 50 ml/min/1.73 m2.
- Subjects or legal guardians must give written informed consent.
- Female patients of childbearing potential cannot be pregnant or lactating/breast-feeding and must be either surgically sterile, postmenopausal (no menses for the previous 12 months), or must be practicing an effective method of birth control as determined by the investigator (e.g., oral contraceptives, double barrier methods, hormonal injectable or implanted contraceptives, tubal ligation, or partner with vasectomy).
- Less than or equal to 45 years of age.
- Patients with cirrhosis, extensive bridging hepatic fibrosis, or active hepatitis are excluded from enrollment.
- Uncontrolled infection or severe concomitant diseases, which in the judgment of the Principal Investigator, indicate that the patient could not tolerate reduced intensity transplantation.
- Severe impairment of functional performance as evidenced by a Karnofsky score <70% (patients ≥16 years old) or Lansky (children <16 years old) score <70%
- Renal insufficiency (GFR <50 ml/min/1.73 m2).
- Subjects with a positive human immunodeficiency virus (HIV) antibody test result.
- Subjects who are pregnant, as indicated by a positive serum human chorionic gonadotrophin (HCG) test.
- Subjects whose only donor is pregnant at the time of intended transplant.
- Subjects of childbearing potential who are not practicing adequate contraception as defined by the investigator at the site.
- Allogeneic hematopoietic stem cell transplant within the previous 1 year.
- Subjects must not have had previous radiation therapy that would preclude total body irradiation (TBI) (as determined by a radiation therapist).
- Jehovah's Witness unwilling to be transfused .
- Uncontrolled hypersplenism.
- Severe alloimmunization with inability to guarantee a supply of adequate packed red blood cell (PRBC) donors.
- Subjects with thalassemia who are Lucarelli Class 3
- Fanconi anemia.
- Insufficient funds for the bone marrow processing costs
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01419704
|United States, Illinois|
|Northwestern Memorial Hospital|
|Chicago, Illinois, United States, 60611|
|United States, Kentucky|
|University of Louisville|
|Louisville, Kentucky, United States, 40202|
|United States, North Carolina|
|Duke University Medical Center|
|Durham, North Carolina, United States, 27705|
|Study Director:||Suzanne T Ildstad, MD||Talaris Therapeutics Inc.|
|Responsible Party:||Talaris Therapeutics Inc.|
|Other Study ID Numbers:||
|First Posted:||August 18, 2011 Key Record Dates|
|Last Update Posted:||March 3, 2023|
|Last Verified:||March 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Marrow/Enriched Hematopoetic Stem Cell Transplant
Bone Marrow Failure Disorders
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Genetic Diseases, Inborn
Bone Marrow Diseases
Anemia, Hypoplastic, Congenital
Red-Cell Aplasia, Pure
Congenital Bone Marrow Failure Syndromes